What is the main business of MCM Polimedica 2?

The main business activity of MCM Polimedica 2 focuses on other human health activities not elsewhere classified.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on February 1, 2022.

Where is the headquarters located?

The headquarters is located at: ul. Belgradzka 52, 02-793 Warszawa.

Who is on the management board?

The management board includes Barbara Kaczmarek (Member of the Management Board).

What is the share capital?

The share capital of the company is PLN 5,250 (approx. $1,418).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.

What was the revenue?

In 2024, the company's revenue reached $504,268.

No, in 2024 the company was not profitable, reporting a net loss of $7,271.

What is the main operating cost?

The largest operating cost category falls under external services. This category amounted to $291,022 in 2024, representing 78% of all operating expenses.

MCM Polimedica 2sp. z o.o.

Other human health activities not elsewhere classified

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2022-02-01

Share capital

5,250.00 PLN

Activity description

MCM Polimedica 2 conducts clinical trials for patients and companies. It provides care in fields including pulmonology, diabetology, cardiology, neurology, gynecology, urology, orthopedics, dermatology and ophthalmology.

Registered address

ul. Belgradzka 52/54, 02-793 Warszawa, Poland

Website

mcmpolimedica.pl

Opening hours

Monday–Friday: 8:00–16:00

Phone

Social media

Financials

Revenue history (in k)

Filing timeliness

2 of 5 financial statements were filed late (the longest delay 360 days for 2022). 1 of 5 audited by a statutory auditor.

202515/07/2026
202412/07/2025
202309/07/2024
202209/07/2024
202126/09/2022

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 330.44kMedianUSD 91.95kAverageUSD 1.38m

Net profit

This companyUSD -1.05kMedianUSD 2.66kAverageUSD 145.95k

Operating costs

This companyUSD 239.15kMedianUSD 82.81kAverageUSD 1.19m

Assets

This companyUSD 670.41kMedianUSD 39.40kAverageUSD 951.16k

Industry

Offer

Clinical trials
Pulmonology clinic
Diabetology clinic
Cardiology clinic
Neurology clinic
Gynecology clinic
Vaccinations

Website technology

Website

WordPress

Authorized Representatives

Maciej Andrzej Stawowski – Attorney-in-fact (sole)

Barbara Kaczmarek – Management Board Member

Iwo Gabrysiak – Attorney-in-fact (sole)

Manner of representation

Each member of the management board is authorised to make declarations on behalf of the company independently.

Ownership

Owner	Shares	Share value	Stake
Piotr Furmanage 39	12	$162.07	11.4286%
Barbara Kaczmarekage 59	21	$283.63	20%
Karolina Anna Kursaage 50	12	$162.07	11.4286%
Robert Mordakaage 60	21	$283.63	20%
Andrzej Piotr Opadczukage 56	39	$526.74	37.1429%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2016-09-16.

ING Bank Śląski
34 1050 1012 1000 0090 3198 6988
ING Bank Śląski
79 1050 1012 1000 0090 3198 6954
ING Bank Śląski
35 1050 1012 1000 0090 3198 6970

Debt

No entries in the National Debtors Register (KRZ).

Real estate

Type	Amount
Land (incl. perpetual usufruct)	$76,614$76,614
Buildings and premises	$508.5K$508,509

Public aid

10 public aid cases recorded, with a total value of $217,920.

Grant date	Purpose	Gross amount	Granting body
May 19, 2023	De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)	$12,184$12,184	Prezes Banku Gospodarstwa Krajowego
May 14, 2021	De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)	$13,247$13,247	Prezes Banku Gospodarstwa Krajowego
Sep 20, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	$2,489$2,489	Prezes Zakładu Ubezpieczeń Społecznych

Regulatory authorisations

Authority	Type	Status
BDO	BDO register entry	Active

Competitors

Name	Revenue	Website
Metromedicasp. z o.o.	$554,556.92	metromedica.pl
Klinika 37sp. z o.o. + limited partnership	$490,176.54	klinika37.pl
Arkmedicsp. z o.o.	$462,335.60	arkmedic.pl
Promedpolsp. z o.o.	$387,938.96	promedpol.pl
Medikussp. z o.o.	$382,326.59	medikus.pl
Hipermedica Centrum Medycznesp. z o.o.	$363,690.08	hipermedica.com.pl
Medcare Groupsp. z o.o.	$356,511.18	medcarejozefow.pl
Evimedsp. z o.o.	$372,683.65	evimed.com.pl
Ken-Medsp. z o.o.	$312,588.47	ken-med.pl
Prof-Medicosp. z o.o.	$280,896.72	prof-medico.pl